PER 3.53% 8.2¢ percheron therapeutics limited

How does ATL1102 compare with Vamorolone, page-8

  1. 860 Posts.
    lightbulb Created with Sketch. 824
    Hi uboy, hopefully these comments by goolsbee will soon be prophetic
    Any progression, anywhere, will require final trial results. Not long now.

    But in a vicious circle, while the Sarepta drug may slow the progression of the disease it can’t stop the disease-created inflammation that keeps attacking the muscle.
    The Antisense treatment is designed to treat the inflammation that exacerbates muscle fibre damage.
    This can be managed by using cortico-steroids but these come with a whole range of side effects including excessive weight gain — precisely the wrong thing for boys who already have limited movement.
    $$$$“What we want to do is add our treatment ATL1102 on top of that drug$$$$ and eliminate a substantial portion of continued muscle degeneration, so whatever the period of ambulation is for that boy would be longer – years is our expectation,” Mr Goolsbee said.
    “We can almost create a position of stasis of the disease.”
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
-0.003(3.53%)
Mkt cap ! $85.01M
Open High Low Value Volume
8.5¢ 8.6¢ 8.2¢ $103.7K 1.237M

Buyers (Bids)

No. Vol. Price($)
3 204084 8.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 280000 3
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.